Loading…
Wednesday January 22, 2025 9:50am - 10:20am EST
This panel will explore how agentic AI and human intelligence will transform drug development, from early-stage discovery and target identification to optimizing clinical trials and advancing personalized treatments. Key topics include AI’s role in accelerating research, improving trial design, and enhancing patient recruitment. The discussion will also address the challenges of understanding complex biology, ensuring data quality, and fostering cross-industry collaboration. By harnessing collective intelligence, the panel will highlight how these technologies can drive innovation, efficiency, and personalization across the drug development pipeline by harnessing collective intelligence.
Moderators
avatar for Stephanie Butler

Stephanie Butler

Senior Conference Production Director, Fierce Life Sciences
Stephanie Butler is a Senior Conference Production Director with Fierce Life Sciences. Previously, Ms. Butler was a Division Manager at the American Conference Institute where she was responsible for the for the creation and development of legal and business conferences in the Pharmaceutical/Life... Read More →
Speakers
avatar for Thomas Clozel, MD

Thomas Clozel, MD

Co-Founder & CEO, Owkin
Thomas is the CEO and Co-Founder of Owkin, leading medical research and business intelligence. He is a former Assistant Professor of Clinical Onco-Hematology at Hopital Henri Mondor in Paris and a former member of Ari Melnick’s lab at Weill Cornell Medical College, where he co-led... Read More →
avatar for Emmanuel Frenehard

Emmanuel Frenehard

Executive Vice President, Chief Digital Officer, Sanofi
Emmanuel Frenehard oversees Sanofi’s digital, data and technology strategy to help transform the practice of medicine, empower healthcare professionals, and better serve patients.Emmanuel joined Sanofi four years ago. Prior to being appointed Chief Digital Officer, he held the positions... Read More →
avatar for Jorge S. Reis-Filho, MD PhD FRCPath

Jorge S. Reis-Filho, MD PhD FRCPath

VP Cancer Biomarker Development, Early Oncology,, AstraZeneca
Jorge S. Reis-Filho is the VP, Cancer Biomarker Development at AstraZeneca, whose mission is to develop mechanistically-informed but clinically-deployable biomarkers to deliver the right therapeutic agents to cancer patients at the right time during their therapeutic journey. Dr... Read More →
avatar for Greg Meyers

Greg Meyers

Executive Vice President, Chief Digital & Technology Officer, BMS
Greg Meyers, executive vice president and chief digital and technology officer, leads the company’s efforts to coalesce digital technology alongside the company's transformational science to get more medicines, to more patients, faster and more impactfully.In his role, Greg leads... Read More →
Wednesday January 22, 2025 9:50am - 10:20am EST
Virtual

Log in to save this to your schedule, view media, leave feedback and see who's attending!

Share Modal

Share this link via

Or copy link